Transmission Of Tuberculosis Among illicit drug use Linkages (TOTAL): A cross-sectional observational study protocol using respondent driven sampling.

Journal: PloS one

Volume: 17

Issue: 2

Year of Publication: 2022

Affiliated Institutions:  Alcohol, Tobacco and Other Drug Research Unit, South African Medical Research Council, Tygerberg, South Africa. Section of Infectious Diseases, Department of Medicine, Boston University School of Medicine, Boston, MA, United States of America. DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research and South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa. Brewelskloof Hospital, Worcester, South Africa. Desmond Tutu Health Foundation, UCT Faculty of Health Sciences, Observatory, Cape Town, South Africa. Department of Biostatistics, Boston University School of Public Health, Boston, MA, United States of America. Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC, United States of America.

Abstract summary 

People who use illicit drugs (PWUDs) have been identified as a key at-risk group for tuberculosis (TB). Examination of illicit drug use networks has potential to assess the risk of TB exposure and disease progression. Research also is needed to assess mechanisms for accelerated TB transmission in this population. This study aims to 1) assess the rate of TB exposure, risk of disease progression, and disease burden among PWUD; 2) estimate the proportion of active TB cases resulting from recent transmission within this network; and 3) evaluate whether PWUD with TB disease have physiologic characteristics associated with more efficient TB transmission. Our cross-sectional, observational study aims to assess TB transmission through illicit drug use networks, focusing on methamphetamine and Mandrax (methaqualone) use, in a high TB burden setting and identify mechanisms underlying accelerated transmission. We will recruit and enroll 750 PWUD (living with and without HIV) through respondent driven sampling in Worcester, South Africa. Drug use will be measured through self-report and biological measures, with sputum specimens collected to identify TB disease by Xpert Ultra (Cepheid) and mycobacterial culture. We will co-enroll those with microbiologic evidence of TB disease in Aim 2 for molecular and social network study. Whole genome sequencing of Mycobacteria tuberculosis (Mtb) specimens and social contact surveys will be done for those diagnosed with TB. For Aim 3, aerosolized Mtb will be compared in individuals with newly diagnosed TB who do and do not smoke illicit drug. Knowledge from this study will provide the basis for a strategy to interrupt TB transmission in PWUD and provide insight into how this fuels overall community transmission. Results have potential for informing interventions to reduce TB spread applicable to high TB and HIV burden settings. Trial registration: Clinicaltrials.gov Registration Number: NCT041515602. Date of Registration: 5 November 2019.

Authors & Co-authors:  Carney Tara T Rooney Jennifer A JA Niemand Nandi N Myers Bronwyn B Theron Danie D Wood Robin R White Laura F LF Meade Christina S CS Chegou Novel N NN Ragan Elizabeth E Walzl Gerhard G Horsburgh Robert R Warren Robin M RM Jacobson Karen R KR

Study Outcome 

Source Link: Visit source

Statistics
Citations :  World Health Organization. Global Tuberculosis Report 2020. World Health Organization: Geneva; 2021.
Authors :  14
Identifiers
Doi : e0262440
SSN : 1932-6203
Study Population
Male,Female
Mesh Terms
Adolescent
Other Terms
Study Design
Cross Sectional Study
Study Approach
Country of Study
South Africa
Publication Country
United States